Hoth Therapeutics, Inc. financial data

Symbol
HOTH on Nasdaq
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1287% % -5.7%
Debt-to-equity 8% % 3.7%
Return On Equity -131% % -48%
Return On Assets -121% % -48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15,514,312 shares 125%
Common Stock, Shares, Outstanding 15,127,622 shares 119%
Entity Public Float $4,900,000 USD -50%
Common Stock, Value, Issued $1,513 USD 119%
Weighted Average Number of Shares Outstanding, Basic 13,787,159 shares 100%
Weighted Average Number of Shares Outstanding, Diluted 13,787,159 shares 100%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,235,000,000 USD
Research and Development Expense $5,670,746 USD 89%
General and Administrative Expense $6,188,366 USD 32%
Operating Income (Loss) $11,859,112 USD -50%
Nonoperating Income (Expense) $25,137 USD -12668%
Net Income (Loss) Attributable to Parent $11,883,703 USD -51%
Earnings Per Share, Basic 0 USD/shares 28%
Earnings Per Share, Diluted 0 USD/shares 28%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $7,847,911 USD -1.9%
Assets, Current $8,921,552 USD 2.8%
Operating Lease, Right-of-Use Asset $11,464 USD -66%
Other Assets, Noncurrent $85,041 USD
Assets $9,244,530 USD 5.7%
Accounts Payable, Current $400,067 USD -21%
Accrued Liabilities, Current $599,018 USD 118%
Liabilities, Current $1,012,684 USD 25%
Operating Lease, Liability, Noncurrent $2,709 USD -90%
Liabilities $1,012,684 USD 25%
Accumulated Other Comprehensive Income (Loss), Net of Tax $11,028 USD -57%
Retained Earnings (Accumulated Deficit) $70,191,154 USD -20%
Stockholders' Equity Attributable to Parent $8,231,846 USD 3.7%
Liabilities and Equity $9,244,530 USD 5.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $2,788,025 USD -62%
Net Cash Provided by (Used in) Financing Activities $7,066,964 USD
Common Stock, Shares Authorized 50,000,000 shares 0%
Common Stock, Shares, Issued 15,127,622 shares 119%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7,847,911 USD -2.2%
Deferred Tax Assets, Valuation Allowance $17,671,982 USD 16%
Deferred Tax Assets, Gross $17,671,982 USD 16%
Operating Lease, Liability $13,599 USD -60%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $11,898,291 USD -51%
Lessee, Operating Lease, Liability, to be Paid $13,946 USD -61%
Operating Lease, Liability, Current $13,599 USD -56%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,732 USD -90%
Lessee, Operating Lease, Liability, to be Paid, Year One $5,750 USD -82%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $347 USD -80%
Deferred Tax Assets, Operating Loss Carryforwards $13,388,457 USD 14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Operating Lease, Payments $2,732 USD
Additional Paid in Capital $78,410,459 USD 18%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $1,410,570 USD 74%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%